Comparison of in vitro efficacy of ozenoxacin vs mupirocin vs fusidic acid against gram positive organism
Not Applicable
- Conditions
- Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue
- Registration Number
- CTRI/2022/09/045794
- Lead Sponsor
- SIKSHA O ANUSANDHAN university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients more than 2 months of age with pyoderma
Exclusion Criteria
1.Pregnancy and lactation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The identification and sensitivity pattern will be performed by Vitek 2, Biomerieux. MIC will be performed by micro broth dilution technique for ozenoxacin, mupirocin and fusidic aciTimepoint: Baseline and after 5 days
- Secondary Outcome Measures
Name Time Method Susceptibility will be determined using breakpoints set by the CLSI for ozenoxacin and that British Society for Antimicrobial Chemotherapy (BSAC) breakpoints will be used for fusidic acid and mupirocin against staphylococci . Standard statistical methods will be used to calculate MIC50 and MIC90.Timepoint: Baseline, after 5 days